COVID-19 IMMUNOLOGIC ANTIVIRAL THERAPY WITH OMALIZUMAB (CIAO TRIAL) - AN ADAPTIVE PHASE II RANDOMIZED-CONTROLLED CLINICAL TRIAL

Registry ID

CIAO_COVID20

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE2

Study type

INTERVENTIONAL

Sponsor

RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE

Start date

2021-12-15

Last update

2020-12-21

Conditions

• CORONAVIRUS DISEASE (COVID-19)

Related clinical trials

• ADAPTIVE PLATFORM TRIAL OF TREATMENTS FOR RESPIRATORY INFECTIONS IN COMMUNITY SETTINGS (TREATRESP)
• AN INTERVENTIONAL EFFICACY AND SAFETY, PHASE 3, DOUBLE-BLIND, 2-ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NON-HOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID-19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS
• PHASE 1/2 STUDY TO EVALUATE SAFETY AND IMMUNOGENICITY OF A PROPHYLACTIC PLASMID DNA BOOSTER VACCINE AGAINST SARS-COV- -002] IN GENERALLY HEALTHY ADULTS 18 YEARS AND OLDER
• A PHASE 2 TRIAL TO EVALUATE SAFETY AND IMMUNOGENICITY OF A NEXT-GENERATION COVID-19 VACCINE DELIVERED BY INHALED AEROSOL TO HUMANS
• A PHASE I/III RANDOMIZED, DOUBLE-BLIND STUDY TO EVALUATE THE SAFETY AND NEUTRALIZING ACTIVITY OF AZD5156/AZD3152 FOR PRE-EXPOSURE PROPHYLAXIS OF COVID-19 IN PARTICIPANTS WITH CONDITIONS CAUSING IMMUNE IMPAIRMENT
• PLATFORM OF RANDOMIZED ADAPTIVE CLINICAL TRIALS IN CRITICAL ILLNESS (PRACTICAL) RANDOMIZED CONTROL TRIAL

View on source registry